Zobrazeno 1 - 10
of 172
pro vyhledávání: '"C. Wasastjerna"'
Autor:
Maria C. Wasastjerna
Publikováno v:
European Business Law Review. 30:337-365
The article examines the implications of big data for competition law, with a focus on personal data and the privacy concerns that such data may give rise to, especially in the area of merger control. Today, one of the biggest challenges for competit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::434b9a4902739db0ffc6b09d3221868c
https://doi.org/10.54648/eulr2019017
https://doi.org/10.54648/eulr2019017
Autor:
Maria C. Wasastjerna
Publikováno v:
European Competition Journal. 14:417-444
The article examines the implications of big data for competition law, with a focus on personal data and the concerns that data may give rise to in merger review. One of the biggest challenges for ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b949597f43563b7cc992cb8e56187c4
https://doi.org/10.1080/17441056.2018.1533364
https://doi.org/10.1080/17441056.2018.1533364
Autor:
Maria C. Wasastjerna
Publikováno v:
SSRN Electronic Journal.
Big data is the hot buzzword across industries and data is playing an increasingly important role in how businesses compete on the markets. In the digital economy, big data represents a core economic asset that can create significant competitive adva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::09cbb07d7ab8121ffe5906fe4094b155
https://doi.org/10.2139/ssrn.3073014
https://doi.org/10.2139/ssrn.3073014
Autor:
Tuomo Timonen, S. Rosengård, Olof Selroos, Eero Ikkala, Reino Lahtinen, Ilmari Palva, Seppo Sarna, A. Hänninen, M. Lehtinen, E. Waris, Pekka Vuopio, C. Wasastjerna, E. Niskanen, Tapani Ruutu, A. Rajamäki, Juhani Vilpo, A. Levanto, P. Ahrenberg
Publikováno v:
Scandinavian Journal of Haematology. 23:119-123
During 5 years 203 adults with acute leukaemia were treated with a combination of daunorubicin, cytararabine and prednisone in the trials of the Finnish Leukaemia Group (FLG). The participating hospitals were classified according to size into 3 group
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4646d7aca8dc15a4f7d196a6090f70e
https://doi.org/10.1111/j.1600-0609.1979.tb02682.x
https://doi.org/10.1111/j.1600-0609.1979.tb02682.x
Autor:
J. Jouppila, Juhani Vilpo, E. Järvenpää, M. Kááriáinen, C. Wasastjerna, Heikki Hallman, Allan Rajamäki, A. Hänninen, G. Järventie, D. Nyman, Erkki Elonen, J. Savola, I. P. Palva, S. Pakkala, Tapani Ruutu, K. Soininen, B. Isomaa, T-T. Pelliniemi, P. Nyländen, E. Koivunen, T. Oivanen, H. Mäkelä, K. Kätkä, Reino Lahtinen, T. Pulli, M. Lehtinen, A. Laitinen, A. Almqvist, Tuomo Timonen, H. Kilpi, K. Ala Harja, P. Ahrenberg, M. Ilvonen
Publikováno v:
European Journal of Haematology. 44:121-124
94 patients with refractory multiple myeloma were treated in a multicentre trial with combinations of cytotoxic drugs including anthracyclines. All were refractory to a 5-drug combination containing 3 alkylating agents, vincristine and methylpredniso
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c6c38882c057c4fbd001103386004e76
https://doi.org/10.1111/j.1600-0609.1990.tb00362.x
https://doi.org/10.1111/j.1600-0609.1990.tb00362.x
Autor:
C. Wasastjerna
Publikováno v:
Scandinavian Journal of Haematology. 4:380-384
This is a case report on a male technician, 37 years of age, who experienced 5 acute episodes of severe thrombocytopenia, which occurred regularly every 21st day. The bleeding episodes usually lasted 12 days, and the remissions 9 days. Treatment with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3e8c1de122f999c130bd7fb0d97650c
https://doi.org/10.1111/j.1600-0609.1967.tb01640.x
https://doi.org/10.1111/j.1600-0609.1967.tb01640.x
Autor:
Pirjo Koistinen, H. Kilpi, S. Rosengård, M. Lehtinen, Ala-Harja K, M. Ilvonen, T. Pulli, B. Isomaa, R. Lahtinen, A. Laitinen, Liisa Volin, C. Wasastjerna, E. Koivunen, T. Oivanen, T. Timonen, A. Rajamäki, H. Mäkelä, K. Kätkä, D. Nyman, A. Almqvist, G. Järventie, I. P. Palva, K. Soininen, E. Järvenpää, Juhani Vilpo, Erkki Elonen, Kari Remes, Tarja-Terttu Pelliniemi, A. Hänninen, Tapani Ruutu, Heikki Hallman, P. Nyländen, J. Jouppila, M. Kááriáinen
Publikováno v:
European Journal of Haematology. 51:98-101
In a randomised multicentre trial a combination of methylprednisolone, vincristine, lomustine, cyclophosphamide and melphalan (MOCCA) was compared with the same regimen omitting methylprednisolone after the first course (COLA) in previously untreated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5854540015d91707b04f947f16f00756
https://doi.org/10.1111/j.1600-0609.1993.tb01600.x
https://doi.org/10.1111/j.1600-0609.1993.tb01600.x
Autor:
Heikki Hallman, I. P. Palva, H. Mäkelä, E. Koivunen, A. Hänninen, T. Oivanen, K. Kätkä, J. Apajalahti, J. Tiilikaninen, Reino Lahtinen, Tuomo Timonen, M. Ilvonen, E. Järvenpää, Tarja-Terttu Pelliniemi, T. Pulli, Ala-Harja K, Juhani Vilpo, H. Kilpi, G. Järventie, P. Ahrenberg, E. Korpi, M. Lehtinen, S. Rosengård, E. Waris, A. Almquist, C. Wasastjerna, S. Koistinen, A. Laitinen, A. Rajamäki
Publikováno v:
Scandinavian Journal of Haematology. 35:205-209
A one-armed multicentre trial was conducted in Finland during the period from Jan. 1979 to Feb. 1980 to document the possible beneficial effect of aggressive combination chemotherapy MOCCA on the remission induction and survival in multiple myeloma.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f71c05df3bfb736e26950266f7f37379
https://doi.org/10.1111/j.1600-0609.1985.tb01574.x
https://doi.org/10.1111/j.1600-0609.1985.tb01574.x
Autor:
E. Koivunen, A. Almqvist, H. Kilpi, K. Ala-harja, K. Soininen, K. Kätkä, C. Wasastjerna, Ilmari Palva, P. Ahrenberg, J. Jouppila, H. Hallman, A. Hävninen, E. Järvenpää, H. Mäkelä, E. Waris, P. Nyländen, S. Koistinen, A. Laitinen, T. Pijlli, Reino Lahtinen, M. Ilvonen, B. Isomaa, T. Oivanen
Publikováno v:
Leukemia & Lymphoma. 2:127-129
The actual use of hospital beds for patients with multiple myeloma was calculated from a randomised trial of primary treatment with either melphalan and prednisone (MP, 66 patients) or intensive combination chemotherapy with vincristine, cyclophospha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8e57cfcc6f913088987508b1cd5d150
https://doi.org/10.3109/10428199009042522
https://doi.org/10.3109/10428199009042522